On Monday, CFRA made an adjustment to the financial outlook for Chemours Co (NYSE:CC), increasing the price target from $17.00 to $18.00 while maintaining a Strong Sell rating on the company's shares. The new target is based on a 6x multiple of the revised earnings per share (EPS) estimate for 2025, which is still below the company's historical forward average. This revision reflects concerns about near-term fundamentals and ongoing litigation issues.
Chemours reported a fourth-quarter EPS of $0.31, surpassing the consensus by $0.07 and showing a significant increase from the $0.07 reported in the same quarter of the previous year. Despite this beat, CFRA has retained its EPS forecast for 2024 at $2.93 and raised its 2025 projection by $0.31 to $3.07. The firm's analysis suggests that the increase in the target price is driven by these revised earnings expectations.
For the first quarter of 2024, Chemours has provided guidance anticipating a 2% sequential decline in revenue and a 3% sequential increase in EBITDA. Notably, the company has not issued full-year guidance, which CFRA interprets as an indication of uncertainty regarding the duration of the Titanium Technologies segment's low cycle. This segment, which constituted 48% of fourth-quarter net sales, is the largest within Chemours.
In addition to the financial guidance, Chemours has also projected a 15% rise in titanium volumes for the second quarter. However, CFRA expresses concern that this volume growth might be accompanied by weaker pricing. The analyst's comments suggest that while Chemours strives for cost leadership in the industry, this approach could potentially limit growth opportunities when the market eventually recovers.
InvestingPro Insights
As Chemours Co (NYSE:CC) navigates through its financial and operational challenges, insights from InvestingPro can provide a deeper understanding of the company's current market position. According to the latest real-time data, Chemours has a market capitalization of $4.28 billion, which reflects investor valuation of the company. Despite not being profitable over the last twelve months, Chemours has been trading at a high Price / Book multiple of 5.81, indicating a premium compared to its book value.
InvestingPro Tips reveal that management's confidence in the company's prospects is evident through aggressive share buybacks, and analysts are optimistic, predicting that the company will turn profitable this year. Additionally, the company has shown a strong return over the last month with a 26.37% increase, although investors should be aware of the stock's volatility. For those looking for more comprehensive analysis, InvestingPro offers numerous additional tips that could guide investment decisions.
For readers interested in a more detailed investment strategy regarding Chemours, utilizing the InvestingPro platform could prove valuable. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.